The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and Crohn’s disease after one systemic therapy if TNF blockers are inadvisable.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-grants-rinvoq-updated-indication-ibd-2025a1000rph?src=rss
Author :
Publish date : 2025-10-14 16:08:00
Copyright for syndicated content belongs to the linked Source.
